Past Meetings

Click on the paperclip at the top of the page to add, remove or edit files. If possible, please add a row to the table below to allow easy access to your slides.

 

9 May 2012

PUW1

Joanna

Immunology

16 May 2012

WCJ

Angelina

Zidovudine PK/PG

23 May 2012

PUW2

Jig

LMWH in pregnancy

30 May 2012

No meeting



6 June 2012

PUW1

Joe

Antimicrobial PKPD

13 June 2012

PUW1

Terry Shepard

Geriatric PKPD

20 June 2012

PUW2

Rollo/Joanna

Immunology modelling

27 June 2012

No meeting



4th July 2012

No meeting



11th July 2012

PUW2

Julie

PAGE review

18th July 2012

PUW2

Katie

Gentamicin in burns

12/10/12 1pm

WCA

Rollo

Modelling of the immune reconstitution post BMT

19/10/12 1pm

PUW3

Joe

Prague Biometrics 2012;68:902-11

26/10/12 1pm

PUW3

Charlotte

NAPPA (Beta lactam pharmacokinetics/pharmacodynamics) plans

2/11/12 1pm

PUW3

Eva

Neogent (developing Bayesian therapeutic drug monitoring) progress

9/11/12 1pm

PUW3

Joanna

Inference methods course review

16/11/12 1pm

PUW2


General discussion

23/11/12 1pm

PUW3

Julie

Covariate selection methods in pharmacokinetic modelling

30/11/12 1pm

PUW3

Julie

NCA versus modelling in phase I studies for drugs with long half-life

7/12/12 1pm

PUW3


Goldacre talk

14/12/12 1pm

PUW3

Lilia

Neutropenia post-BMT

4/1/13 1pm

PUW3


General discussion

11/1/13 1pm

Levinsky

Joe

Maraviroc PK

18/1/13 1pm

PUW4

Andrezj

PKPD bridging of response between adults and children

25/1/13 1pm

PUW3

Lilia

Neutropenia following paediatric BMT

1/2/13 1pm

PUW1

Mirjam Trame

Use of PKPD modeling to guide HIV understanding and treatment

8/2/13 1pm

PUW3

Sami

Bioequivalence studies and genetic variability

15/2/13 1pm

PUW1

Liana

ErbB inhibition for PKD

22/2/13 1pm

PUW3

Alienor Berges (GSK)


1/3/13 1pm

PUW4

Rollo

CD4 reconstitution post BMT 

8/3/13 1pm

PUW3

Eva

Neogent update

15/3/13 1pm

PUW4

Tafi

Dose individualisation in HIV/AIDS and TB patients on Efavirenz (EFV).

22/3/13 1pm

PUW3

Hui Ma

Genetic components to glucose-insulin response

26/4/13 1pm

PUW3

Sarit

FA and bioavailability

10/5/13 1pm

PUW3

Tafi

Common adverse drug reactions linked to HIV and/or TB medication: Lipodystrophy, Skin Hypersensitivity, CNS and Peripheral Neuropathy.
(To appear in the Journal of AIDS and Clinical Research, 2013).

28/5/13 1pm

PUW1

Charlotte

Use of meta-analysis in evidence synthesis: an example  based on dose selection for antibiotics (PAGE talk)

31/5/13 1pm

PUW1

Rollo

Modelling immune reconstitution in children post HSCT (PAGE talk)

7/6/13 1pm

PUW3

Julie

Penalized regression implementation within the SAEM algorithm to advance high-throughput personalized drug therapy (PAGE talk)

21/6/13 1pm

PUW1

Bruce Green

Therapeutic Drug Monitoring

16/9/13 1pm

PUW3

Joe

Diagnostics for bivariate regression models

23/9/13 1pm

PUW3

No meeting

Julie Seminar on Tues 24/9.

30/9/13 1pm

PUW2

Jan-Stefan Van der Walt

Nonlinear mixed effects model for saliva cortisol and cortisone in patients with Addisons disease and healthy volunteers.

1/10/13 1pm EXTRA MEETING

PUW4

Stefanie Hennig

Changes in between subject variability with covariate models in pharmacometrics

7/10/13 1pm

PUW2



14/10/13 1pm

PUW3

Tafi

TBA

21/10/13 1pm

PUW2

Julie

Modelling of tenofovir and emtricitabine PK in the ANRS 134-COPHAR 3 trial (work in progress)

28/10/13 1pm

PUW3

Joanna

CD4 recovery in the CHER study

4/11/13 1pm

PUW2

Eva

Upgrade talk practice

11/11/13 1pm

PUW3

Flora Musuamba

Use of modelling and simulation tools to improve decision-making in drug development and clinical practice

18/11/13 1pm

PUW2

Joe

Decision theory and antimicrobials

25/11/13 1pm

PUW3

Andreas

Pain PKPD

2/12/13 1pm

TWC F

No meeting


9/12/13 1pm

PUW3

Pieter de Cock

Paediatric antimicrobial PKPD in ICU

16/12/13 1pm

PUW3

Rollo

Modelling TCR repertoire (not with NLME!)

20/1/14

PUW3

Jessica Soto

Modelling taste studies

27/1/14

PUW1

Joanna

Practice for South Africa

3/2/14

PUW3

Liana

PK of tyrosine kinase inhibitors in PKD animal model

10/2/14

PUW4

Eva

Neogent predictions

17/2/14

PUW3

Deji

Hepatitis and HIV co-infection modelling

24/2/14

PUW1



3/3/14

PUW2

Rollo

Upgrade practice

10/3/14

PUW1

Joe

Clonidine PKPD for sedation in PICU

17/3/14

PUW3

Andreas

Clinical protocol development for GAbapentine in Paediatric pain Project : Optimization of the trial design characteristics based on (E)D optimality using popED.

24/3/14

PUW3

Julie

MRC Biostats talk on new methods for genetic covariates in PKPD modelling.

31/3/14

PUW1

Flora

Clinical protocol development for GAbapentine in Paediatric Pain Project : Dose rationale and dosing schedule for characterisation efficacy in chronic pain

7/4/14

PUW3

Morris

Development and dose rationale for fixed dose combinations for the treatment of tuberculosis

14/4/14

WCD

Andrezj

Population Pharmacokinetic Analysis of Efavirenz in African Children using mixture modelling to describe clearance multimodality

26/4/14

PUW4



12/5/14

PUW2

Carlos Hoyo

Nifedipine PKPD

19/5/14

WCC

Gavin Jarvis

A Modelling Approach to the Genetics of Embryonic Growth

23/6/14

PUW3

All

PAGE meeting review

30/6/14

PUW2

Flora

NLME cluster demonstration

7/7/14

PUW1

Sophie Rhodes

The immune response to BCG vaccination over time and the population variation of immune response dynamics

14/7/14

PUW2

Joanna and Jamie

An ODE model of peptide presentation by MHC-I / Geometric MCMC




SUMMER

1/9/14

LGSR

Joe

Antimicrobial PKPD   IDM_clinpharm_Standing_2014.pdf

8/9/14 meeting starts 2pm

Levinski

Julie

DDMore language

15/9/14

LGSR

Paul

Pharmacogenetics of diclofenac

22/9/14

LGSR

Yucheng

Count data models and introduction to Pirana

29/9/14

LGSR

Andreas

Gabapentin PKPD in paediatric neuropathic pain

6/10/14

LGSR

Liana

Tyrosine kinase inhibitor effects in polycystic kindney disease

13/10/14

LGSR

Joanna


20/10/14

LGSR

Rollo

Short-term neutrophil and lymphocyte HSCT models

27/10/14

LGSR

Eva

NeoGent PKUK practice

3/11/14

LGSR

Seb

Item Response Theory: Application to NLME

10/11/14

LGSR

Joe

A new mechanistic model for antiretroviral pharmacodynamics 

17/11/14

LGSR

Alberto

Anaesthesia depth with 3 different EEG measures

24/11/14

LGSR

Suzanne Reeves

Mechanisms underpinning antipsychotic sensitivity in Alzheimer's disease

1/12/14

LGSR

Deji

Mixed Effect Modelling in Hep C-HIV coinfected children

8/12/14 meeting starts at 2pm

LGSR

TBC

To be confirmed

15/12/14

LGSR

Morris

Understanding the determinants of drug exposure and pharmacokinetic variability in tuberculosis patients

Date

Location*

Presenter

Topic

12/1/15PUW3Lynette PheeModelling antimicrobial synergy
19/1/15PUW3Michael BetancourtBayesian approaches in NLMEM
26/1/15PUW4Dejipre-Upgrade Talk
2/2/15PUW3JoeStudy design peer review/journal club
9/2/15PUW3EvaComparing methods for paediatric PK scaling
16/2/15PUW3Ajay SinhaAmikacin and Vancomycin PK in neonates
23/2/15PUW4Julie

Joint modeling of Tenofovir plasmatic and intracellular concentrations - The COPHAR3 trial

2/3/15PUW3Karin SeifertEstablishing PK/PD relationships of anti-leishmanial drugs
9/3/15PUW3JoeAntimicrobial PKPD, refresher and future directions
16/3/15PUW3SophieVaccine dyamics with NLME
23/3/15PUW4SuzanneAmisulpride PKPD
30/3/15PUW3MorrisDeterminants of variability in drug exposure and implications for dose selection in tuberculosis patients
13/4/15PUW2AndreasGabapentin for neuropathic pain
20/4/15PUW3JoeNLME tutorial
27/4/15PUW4YuchengPropofol in ICU
11/5/15PUW3IblalBenzylpenicillin neonatal PK
18/5/15PUW3JoePK of combination therapy in resistant Gm -ves
1/6/15PUW3

8/6/15PUW3LianaPKPD of in vivo PKD model
15/6/15PUW3AllPAGE review
22/6/15PUW3EvaPD neonatal infection modelling
29/6/15PUW4SuzannePKPD of amisulpride
6/7/15PUW3LudoPKPD in veterinary medicine
13/7/15PUW3Roger GunnPK-PD modelling of CNS PET Molecular Imaging Studies
7/9/15PUW3AiweiDexmeditomidine PKPD
14/9/15PUW3EvaMeropenem in late onset sepsis and meningitis in neonates
21/9/15PUW3LudoDexmeditomidine PKPD (in veterinary subjects)
28/9/15PUW3BenModelling HCMV
5/10/15PUW1SuzanneAmisulpride PK update
12/10/15PUW1David MoorePKPD in TB
19/10/15PUW1JoePersonalised medicine with PKPD
26/10/15PUW1Imperial GroupAntimicrobial decision support
2/11/15PUW1

9/11/15PUW2RolloPhD viva prep talk
16/11/15PUW2EvaIRT for neonatal sepsis
23/11/15PUW2FrankPKPD in malaria
30/11/15PUW2Morris

PBPK Modelling in TB

7/12/15PUW2LianaPKD PKPD
14/12/15PUW2Pratima ChowdaryIndividualised dosing in haemophilia

Date


Location*

Presenter

Topic

1/2/16PUW3DejiHIV models in children
4/4/16PUW2MorrisModel-based translational research in tuberculosis

4/7/16

PUW2

AlbertSiRNA PD in neuroblastoma
6/2/16PUW1CharlotteUpdate on NAPPA

6/6/16

PUW2

No meetingPAGE
7/3/16PUW3FrankIn vitro TB PD

9/5/16

PUW3

Joy DawesMorphine and dexmeditomidine PK in children
11/4/16PUW3Oliver StirrupAdult NLME in HIV under HAART

11/7/16

PUW2

No MeetingTo be rescheduled: Min - NAPPA amoxicillin/co-amoxiclav PK results

13/6/16

PUW2

GeorgieFlucloxacillin PK: Neonatal results from NAPPA
14/3/16PUW3JulieBayesian inference in high-throughput pharmacogenetics
15/2/16PUW3YuchengCount data modelling of BATA

16/5/16

PUW3

JulieJoint modelling of plasmatic and intracellular concentrations of Tenofovir (TDF) and Emtricitabine (FTC) - The COPHAR3 trial
18/1/16PUW3Planning meeting
18/4/16PUW3BenIncorporating immunity into CMV models

20/6/16

PUW2

Dan Wright

Model-based dose prediction: the curious case of allopurinol

21/3/16PUW2DejiModelling poor immune response in HIV-infected children
22/2/16PUW3BenCMV model update

23/5/16

PUW2

LetiziaPBPK in TB
25/1/16Levinski roomJoeScaling in PK and PD
25/4/16PUW3Per Olsson

Life as a pharmacometrics consultant

27/6/16

PUW2

Salvo

Neonatal antimicrobial PK

29/2/16PUW2FabriziaPKPD in neurology

Date


Location*

Presenter

Topic

12/9/16PUW4Joanna LewisCHER, chlamydia and reproducibility: a view from Imperial
19/9/16PUW4All
R-script repository
26/9/16PUW4BenCMV PKPD update
3/10/16PUW1Lucy HutcinsonPreclinical PD modelling in oncology
10/10/16PUW1Matt JayBayesian analysis of morphine safety in children
17/10/16PUW1Huixin Yu
PK/PD modelling & simulation for anticancer drugs with complex absorption characteristics
24/10/16PUW1MorrisModelling combination therapy in tuberculosis
31/10/16PUW1Dagan LonsdaleUpdate on ABDose
7/11/16LevinskyAiwei LiDexmeditomidine PKPD
14/11/16LevinskyAmy Cheung/James YatesQSP in paediatrics/Of mice and more
21/11/16LevinskyGraceNeonatal and paediatric antimicrobials
28/11/16Levinsky

5/12/16Levinsky

12/12/16PUW1Chris WPBPK modelling of dexamethasone + selumetinib in combination in adults and children
19/12/16PUW1CharlotteUpdate on NAPPA

Date

Location*

Presenter

Topic

19/12/16 (12:00)PUW1CharlotteUpdate on NAPPA
16/1/17 PUW4FrankPractice MRC interview
23/1/17PUW4JoeFLACSAM PK results
30/1/17PUW4AllPaediatric sample size discussion
6/2/17PUW4FrankUpdate on treosulfan/TB work
13/2/17PUW4Mike and SophidaMRes project outline
20/2/17PUW2BenCMV PD
27/2/17PUW2CharlotteNAPPA update
6/3/17PUW2MorrisRationale for dose selection in tuberculosis: how to scale from mouse to human?
13/3/17PUW2Benjamin Blaise
iSleep/iCare - real-time metabolic support for personalized intensive care
20/3/17PUW2

27/3/17PUW2Aubrey CunninghamAdjunctive therapy for severe malaria
3/4/17PUW2BelenPhD update
10/4/17PUW2

24/4/17PUW1Annegret Dahlmann-noorPKPD in ophthalmology
8/5/17PUW1Paul BaverelTralokinumab, an investigational anti-IL13 monoclonal antibody: PK & exposure-response modeling to bridge adult and paediatrics clinical development plan
15/5/17PUW1MorrisTB modelling PAGE practice
22/5/17PUW1BenCMV modelling ESPID practice
5/6/17PUW1
No meeting
12/6/17 (12:00)PUW3AllPAGE review
19/6/17PUW1LudoHFIM progress
26/6/17PUW1Maria ScarpaEnd-user acceptability of orodispersible films (ODF) for delivery of medicine
3/7/17PUW1

10/7/17PUW1

17/7/17PUW1

30/10/17Levinsky

27/11/17LevinskyWatyCovariate analysis with supervised machine learning
25/9/17PUW2YomnaTreosulfan PK
23/10/17Levinsky

20/11/17Levinsky
Nicolas Fanget
Publishing in Nature journals
18/12/17LevinskyLudoHFIM modelling progress
18/9/17LevinskySophidaPosaconazole pharmacokinetics in children
16/10/17LevinskyMandy WVitamin D PKPD plans
13/11/17LevinskyShan PanApplication of pharmacometrics in rheumatoid arthritis: case studies in clinical practice and drug development
11/12/17LevinskyVickyRivaroxaban PKPD
11/9/17Levinsky
no meeting
9/10/17Levinsky

6/11/17LevinskyJuliePK of serum and intra cellular sustained-release Lithium
4/12/17LevinskyJuliePK of total, unbound and intra cellular MPA
2/10/17LevinskyOfranGender differences in infant mortality in UK PICUs
8/1/18PUW 4planning meeting
15/1/18PUW 4
Haifa
Posaconazole study protocol
22/1/18PUW 4FrankVancomycin PKPD
29/1/18PUW 4DaganResults from ABDose
5/2/18PUW 4ShanSalbutamol PKPD
12/2/18PUW 4DionnaCoMPLEX mini project
19/2/18PUW 3

26/2/18PUW 3BernTB-PRACTECAL trial PK-PD study design
5/3/18Levinski 12:00 startAyeshaRituximab PKPD
12/3/18PUW 3BenStatistical Challenges in T Cell Receptor Repertoire Immunophenotyping
19/3/18PUW 3JoePosaconazole PK
26/3/18PUW 1WatyMachine learning approaches
9/4/18PUW 3

16/4/18PUW 3planning meeting
23/4/18PUW 3no meeting ECCMID
30/4/18PUW 3JigAnticoagulant PKPD in haemodialysis
14/5/18PUW 3FrankModelling progress in TB
21/5/18PUW 3no meeting PK course
4/6/18PUW 3MaddliePhD introduction: PKPD modelling of sedative and analgesic effects
11/6/18PUW 3Komal BhatiaInfant growth in urban informal settlements (slums) in Mumbai, India
18/6/18PUW 3ShanPsoriasis PKPD modelling
25/6/18PUW 3Oleg VolkovOptimal design in PKPD
2/7/18PUW 3BenCMV modelling
9/7/18PUW 3JulieModel-based bioequivalence




3/9/18PUW 3planning meeting
10/9/18PUW3FrankModelling of in vitro antimicrobial experiments
17/9/18PUW3no meeting
24/9/18PUW3SatveerNIHR practice psoriasis TDM
1/10/18PUW1OfranNIHR practice
8/10/18PUW1JulieDynamic individual predictions of biomarker profiles and survival in Oncology with Stan, Monolix and Nonmem
15/10/18PUW1

22/10/18PUW3Rashmi KulkarniMonitoring oxidative stress enables predictions of personalised glucose
targets in diabetic patients
29/10/18PUW3

5/11/18PUW3James Yates
Modelling nonclinical efficacy data for immune-oncology treatments
12/11/18PUW3FrankVancomycin PKPD in children
19/11/18PUW1JohnPhD introduction - nlme in vaccine development
26/11/18LevinskiSoumyaPhD introduction
3/12/18PUW3JayaNeonatal vancomycin CSF PK
10/12/18PUW3Daren AustinOptimised dose for WHO weight bands
7/1/19PUW3Planning meeting
14/1/19PUW3JoeBSAC Antimicrobial chemotherapy meeting practice
21/1/19PUW3

28/1/19PUW3MaddlieClonidine/fentanil PK update
4/2/19PUW1journal club
11/2/19PUW1FrankPredicting clinical outcome in TB
18/2/19PUW1CharlotteNAPPA overview
25/2/19PUW3
Phil Tresadern
popypkpd introduction
4/3/19PUW3SilkePhD work summary
11/3/19PUW3FerranPK paper picking with ML
18/3/19PUW3MaddliePKPD of sedation in neonates
25/3/19PUW3JudePhD Introduction
1/4/19PUW1SoumyaRituximab PD in BMT
8/4/19LEWINSKYZoePhD Introduction
15/4/19PUW3no meetingECCMID
13/5/19PUW3Claire Deakin
Modelling long-term outcomes and estimating treatment efficacy in a rare rheumatic disease
20/5/19PUW3HaifaCaspofungin PK in ECMO
3/6/19PUW1

10/6/19LEVINSKYno meeting
17/6/19PUW3AllPAGE review
24/6/19PUW3CintiaPaediatric Clinical Pharmacology in Buenas Aires
1/7/19PUW3Wen YaoPKPd in Malaysia
8/7/19PUW3JoeTreo PKPD
15/7/19PUW3MaddlieUpgrade practice

Date

Location*

Presenter

Topic

2/9/19LGSRFerranQSP machine learning practice
12/9/19 [NOTE Thurs)PUW2Palang Chotsiri and Richard HoglundMalaria PKPD
16/9/19LGSRPlanning meeting
23/9/19LGSRSimonPeptide PKPD
30/9/19LGSR

7/10/19LGSR

14/10/19LGSRJuliePharmacogenomics and nlme - some applications
21/10/19LGSRFrankTB PKPD
28/10/19LGSRSoumyaB cell reconstitution post HSCT and rituximab
4/11/19LGSRFerranPK parameter extraction with NLP
11/11/19LGSRZoeFosfomycin PK in neonates
18/11/19PUW2JoeMRC interview practice
25/11/19PUW1MaddlieClonidine PKPD in PICU
2/12/19PUW2

9/12/19PUW2SilkeAntimicrobial PKPD
16/12/19PUW2ZahraAntimicrobial in vitro PKPD




Date

Location*

Presenter

Topic

7/9/20microsoft teamsPlanning meeting
14/9/20microsoft teamsJoeSARS-CoV-2 dynamics
21/9/20microsoft teamsSoumyaB cell update
28/9/20microsoft teamsZoeUpgrade practice
5/10/20microsoft teamsMaddlieEAPs conference practice
12/10/20microsoft teamsEmmaEHR Prescribing patterns
19/10/20microsoft teamsJudePhD progress update
26/10/20microsoft teamsMandyColecalciferol in children with chronic kidney disease
2/11/20microsoft teamsMaddlieSANNI update
9/11/20microsoft teamsSilkePTA of antimicrobials
16/11/20microsoft teamsHaifaCaspofungin PK in ECMO
23/11/20microsoft teamsZahraHollow fibre update
30/11/20microsoft teamsZoeBenzinidazole
7/12/20microsoft teamsMattRisperidone study
14/12/20microsoft teamsFrankTB
21/12/20microsoft teamsJamesPK/PD of MDR TB therapy

microsoft teams

Date

Location*

Presenter

Topic

4/1/21microsoft teamsPlanning meeting
11/1/21microsoft teamsJamesPKPD of MDR TB
18/1/21microsoft teamsFerranPKPDai update
25/1/21microsoft teamsSoumyaRituximab PKPD
1/2/21microsoft teamsJulieTModel-based bioequivalence
8/2/21microsoft teamsFerranPKPDai update
15/2/21microsoft teamsSilkeAmp/gent update
22/2/21microsoft teamsSaherTeicoplanin pharmacokinetics
1/3/21microsoft teamsFrankJournal club
8/3/21microsoft teamsNajlaPhD introduction
15/3/21microsoft teamsNadhia
29/3/21microsoft teamsEmmaPre-upgrade




12/4/21microsoft teamsplanning meeting
19/4/21microsoft teamsVijay IvaturiPumasai
26/4/21microsoft teams

10/5/21microsoft teamsJudeTacrolimus update
17/5/21microsoft teamsSoumyaB cell update
24/5/21microsoft teamsLudo
7/6/21microsoft teams

14/6/21microsoft teamsJudeTacrolimus update
21/6/21microsoft teamsFrank/BernTB trial
28/6/21microsoft teamsEmmaUpgrade practice
5/7/21microsoft teamsZoeBenzinidazole
12/7/21


13/9/21microsoft teamsPlanning meeting
20/9/21microsoft teamsAkosuaMechanism based antimicrobial PKPD
27/9/21microsoft teamsZonghuiVitamin D PKPD
4/10/21microsoft teamsSoumyaB cell dynamics under anticancer therapies
11/10/21microsoft teamsQuentinExploring the risk of AMR horizontal gene transfer by transduction in S. aureus during phage-antibiotic co-therapy
18/10/21microsoft teamsEmmaAntimicrobial time series update
25/10/21microsoft teams

1/11/21microsoft teamsFanFavipiravir PKPD
8/11/21microsoft teamsZoePKPD of immunosuppressant-azole interactions
15/11/21microsoft teamsVickyPKPD of rivaroxaban
22/11/21microsoft teamsZahraAntimicrobial in vitro PD
29/11/21microsoft teamsFrankTB Practical
6/12/21microsoft teamsJudeTacrolimus PKPD
13/12/21microsoft teamsNajlaFosfomycin in vitro PKPD
12/1/22PUW4/ microsoft teamsMarie Sjölin Wijk
24/1/22PUW4/microsoft teamsStefano
31/1/22PUW4/microsoft teamsAndrew Mead
7/2/22PUW3/microsoft teamsHuiMachine learning based model fitting
14/2/22PUW3/microsoft teamsCarolBivalirudin PKPD
21/2/22PUW3/microsoft teamsZoePosaconazole PKPD
28/2/22PUW3/microsoft teamsNajlaFosfomycin hollow fibre
7/3/22PUW3/microsoft teamsVicky SmithAutomated parameter extraction
14/3/22PUW3/microsoft teamsAkosua

FLARE trial PKPD

21/3/22PUW3/microsoft teamsFanFavipiravir PKPD
28/3/22PUW3/microsoft teamsEmmaAntimicrobials update
4/4/22PUW3/microsoft teams

25/4/22PUW3/microsoft teamsJudeTacrolimus PKPD
9/5/22PUW3/microsoft teamsHelen ShawPharmacokinetic Challenges for a Children’s Medicine Company
16/5/22PUW3/microsoft teams

23/5/22PUW3/microsoft teamsAmanda GweePaediatric PKPD down under
6/6/22PUW3/microsoft teamsZhonghuiProgress with GA modelling
13/6/22PUW3/microsoft teamsFanFavi update
20/6/22PUW3/microsoft teamsSoumyaB cell dynamics in BMT
27/6/22PUW3/microsoft teamsJamie DeanIntroducing the Computational Radiation Biology and Oncology Lab
4/7/22PUW3/microsoft teams

11/7/22PUW3/microsoft teams

18/7/22PUW3/microsoft teamsEmmaPredicting antimicrobial susceptibility to blood culture results

microsoft teams

16/1/23PUW3/ microsoft teamsSoumyaPhD overview/viva practice
23/1/23PUW3/microsoft teamsShanAdalimumab PKPD
30/1/23PUW3/microsoft teamsSuzannePiperacillin-tazobactam PKPD
6/2/23PUW3/microsoft teamsVickyPhD update
13/2/23PUW3/microsoft teamsLudo/AndrewModelling the effect of Antimicrobial use in poultry on AMR risk in 3 Asian countries / Optimized dosing regimens for the combinations of sulfonamides and trimethoprim in veterinary medicine
20/2/23PUW3/microsoft teamsHuiPhD update
27/2/23PUW3/microsoft teamsJudeTacrolimus PKPD
6/3/23PUW3/microsoft teams

13/3/23PUW3/microsoft teamsRachelProject introduction
20/3/23PUW3/microsoft teamsNajlaSystematic review
27/3/23PUW3/microsoft teamsEmmaAntibiotic prescribing in remote versus face-to-face consultations for acute respiratory infections in English primary care: An observational study using TMLE
17/4/23PUW3/microsoft teamsVickyUpgrade talk
24/4/23PUW3/microsoft teamsNajlaAntimicrobial PKPD systematic review
15/5/22PUW3/microsoft teamsJoePanoramic practice
22/5/22PUW3/microsoft teamsJoeFDA talk practice
5/6/23PUW3/microsoft teamsSimone Perazzolo Introduction to the SAAM2 software
12/6/23PUW3/microsoft teamsHuiPAGE meeting practice
19/6/23PUW3/microsoft teamsHuiPhD upgrade
26/6/23PUW3/microsoft teamsPAGE
3/7/23PUW3/microsoft teamsWCP
10/7/23PUW3/microsoft teamsRachel Clapham PopPk of edoxaban

PUW3/microsoft teams

5/9/22PUW3/ microsoft teamsJeff BarrettModel-informed Pediatric Drug Development
12/9/22PUW3/microsoft teamsAkosuaSARS-CoV-2 viral dynamics
19/9/22PUW3/microsoft teams

26/9/22PUW3/microsoft teamsFanUpgrade practice
3/10/22PUW3/microsoft teamsNajlaUpgrade practice
10/10/22PUW3/microsoft teamsEmma

Antibiotic prescribing and remote consultations in primary care

17/10/22PUW3/microsoft teamsOfranTLMEs
24/10/22PUW3/microsoft teamsFrankACoP practice
31/10/22PUW3/microsoft teamsReyaPKUK practice
7/11/22PUW3/microsoft teamsAllACoP/PKUK review
14/11/22PUW3/microsoft teamsJigFellowship chalkboard
21/11/22PUW3/microsoft teams

5/12/22PUW3/microsoft teamsDolapo OdujinrinIntroduction to PhD project
12/12/22PUW3/microsoft teams









4/9/23PUW3/ microsoft teamsplanning meeting
11/9/23PUW3/microsoft teamsFrankTB modelling update
18/9/23PUW3/microsoft teamsZharaAntimicrobial PKPD
25/9/23PUW3/microsoft teamsLizzyProposal overview 
2/10/23PUW1/microsoft teamsJig PatelFellowship practice
9/10/23PUW1/microsoft teamsJan StefanNONMEM tips and tricks
16/10/23PUW1/microsoft teamsRobAntimicrobial TDM Pro/con debate
23/10/23PUW1/microsoft teamsDolapoInvestigating mechanistic modelling approaches for individualised dosing of cancer therapeutics.
30/10/23PUW1/microsoft teamsFan Ciclosporin
6/11/23PUW1/microsoft teamsJoyNeonatal sedative maturation functions
13/11/23PUW1/microsoft teamsOliverCART preclinical modelling
20/11/23PUW1/microsoft teamsHuiAutomated model building update
27/11/23PUW1/microsoft teamsLizzyRituximab PKPD
4/12/23PUW1/microsoft teamsNajlaSystematic antimicrobial PKPD review
11/12/23PUW1/microsoft teamsAndrew MeadUpdate on antimicrobial PKPD